Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 505 Results

Page 26 of 51« First «...10 20...24 252627 28...40 50...»Last »

January 17, 2019

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

January 3, 2019

DBV Technologies Expands and Strengthens Leadership Team

December 19, 2018

DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age

December 12, 2018

DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018

November 20, 2018

DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children

November 16, 2018

DBV Technologies Appoints Daniel Tassé as Chief Executive Officer

November 9, 2018

DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

October 30, 2018

DBV Technologies Reports September 30, 2018 Cash Position

October 26, 2018

DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers

October 22, 2018

DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration

Page 26 of 51« First «...10 20...24 252627 28...40 50...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top